Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 9/2018

01.09.2018 | Neurological Infectious Diseases

Acute Flaccid Paralysis and Enteroviral Infections

verfasst von: Ari Bitnun, E. Ann Yeh

Erschienen in: Current Infectious Disease Reports | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The focus of this review is on enterovirus (EV)-associated acute flaccid paralysis (AFP) due to spinal cord anterior horn cell disease. Emphasis is placed on the epidemiology, pathogenesis, diagnosis, treatment, and outcome of AFP caused by polioviruses, vaccine-derived polioviruses, EV-D68, and EV-A71.

Recent Findings

Since the launch of The Global Polio Eradication Initiative in 1988, the worldwide incidence of polio has been reduced by 99.9%, with small numbers of poliomyelitis cases being reported only in Afghanistan, Pakistan, and Nigeria. With the planned phaseout of oral polio vaccine, vaccine-associated poliomyelitis is also expected to be eliminated. In their place, other EVs, chiefly EV-D68 and EV-A71, have emerged as the principal causes of AFP. There is evidence that the emergence of EV-D68 as a cause of severe respiratory disease and AFP was due to recent genetic virus evolution. Antiviral medications targeting EV-D68, EV-A71, and other EVs will likely be available in the near future. An effective EV-A71 vaccine has been developed, and preliminary investigations suggest an EV-D68 vaccine could be on the horizon.

Summary

The eradication of poliomyelitis and vaccine-associated poliomyelitis is near, after which other EVs, presently EV-D68 and EV-A71, will be the principle viral causes of AFP. Moving forward, it is essential that EV outbreaks, in particular those associated with neurologic complications, be investigated carefully and the causal strains identified, so that treatment and prevention efforts can be rapidly developed and implemented.
Literatur
1.
2.
3.
Marx A, Glass JD, Sutter RW. Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev. 2000;22(2):298–316.CrossRefPubMed
4.
5.
6.
Romero JR, Dodlin JF. Poliovirus. In: Bennett JE, Dolin R, Blaser MJ, editors. Principles and practive of infectious diseases. Eighth ed. Philadelphia: Elsevier Saunders; 2015. p. 2073–2079.
7.
•• Messacar K, Schreiner TL, Van Haren K, Yang M, Glaser CA, Tyler KL, et al. Acute flaccid myelitis: a clinical review of US cases 2012-2015. Ann Neurol. 2016;80(3):326–38. A comprehensive review of U.S. studies on EV-D68 AFP/AFM. CrossRefPubMedPubMedCentral
8.
Nelson GR, Bonkowsky JL, Doll E, Green M, Hedlund GL, Moore KR, et al. Recognition and management of acute flaccid myelitis in children. Pediatr Neurol. 2016 Feb;55:17–21.
9.
•• Sejvar JJ, Lopez AS, Cortese MM, Leshem E, Pastula DM, Miller L, et al. Acute flaccid myelitis in the United States, August-December 2014: results of nationwide surveillance. Clin Infect Dis. 2016;63(6):737–45. The largest single study pertaining to the 2014 EV-D68 outbreak, consisting of 120 cases of AFP/AFM reported to the CDC. CrossRefPubMed
10.
• Van Haren K, Ayscue P, Waubant E, Clayton A, Sheriff H, Yagi S, et al. Acute flaccid myelitis of unknown etiology in California, 2012-2015. JAMA. 2015;314(24):2663–71. One of the earliest reports of 2014 EV-D68-associated AFP/AFM in the USA. CrossRefPubMed
11.
• Yea C, Bitnun A, Robinson J, Mineyko A, Barton M, Mah JK, et al. Longitudinal outcomes in the 2014 acute flaccid paralysis cluster in Canada. J Child Neurol. 2017;32(3):301–7. A comprehensive Canada-wide review of EV-D68-associated AFP/AFM cases.
12.
•• Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis. 2015;15(6):671–82. A retrospective study of EV-D68-associated AFP/AFM cases that included phylogenetic analysis demonstrating that the 2014 outbreak strain was a B1 clade with potentially significant pathogenic nucleotide polymorphisms.
13.
Weinstein L, Shelokov A, Seltser R, Winchell GD. A comparison of the clinical features of poliomyelitis in adults and in children. N Engl J Med. 1952 Feb 21;246(8):297–302.CrossRefPubMed
14.
• Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015;385(9978):1662–71. One of the earliest reports of 2014 EV-D68-associated AFP/AFM in the USA.
15.
Chen CY, Chang YC, Huang CC, Lui CC, Lee KW, Huang SC. Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates. AJNR Am J Neuroradiol. 2001 Jan;22(1):200–5.PubMedPubMedCentral
16.
• Hu Y, Jiang L, Peng HL. Clinical analysis of 134 children with nervous system damage caused by enterovirus 71 infection. Pediatr Infect Dis J. 2015;34(7):718–23. One of the larger series of EV-A71 neurologic disease in children. CrossRefPubMed
17.
Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999 Sep 23;341(13):936–42.
18.
•• Lee HF, Chi CS. Enterovirus 71 infection-associated acute flaccid paralysis: a case series of long-term neurologic follow-up. J Child Neurol. 2014;29(10):1283–90. A comprehenive case series evaluating the long-term neurologic outcome of EV-A71-associated AFP/AFM. CrossRefPubMed
19.
20.
Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341(13):929–35.CrossRefPubMed
21.
• Teoh HL, Mohammad SS, Britton PN, Kandula T, Lorentzos MS, Booy R, et al. Clinical characteristics and functional motor outcomes of enterovirus 71 neurological disease in children. JAMA Neurology. 2016;73(3):300–7. A large case series of EV-A71-associated neurologic disease in Australia.
22.
Wadia NH, Irani PF, Katrak SM. Lumbosacral radiculomyelitis associated with pandemic acute haemorrhagic conjunctivitis. Lancet. 1973;1(7799):350–2.CrossRefPubMed
23.
Wadia NH, Katrak SM, Misra VP, Wadia PN, Miyamura K, Hashimoto K, et al. Polio-like motor paralysis associated with acute hemorrhagic conjunctivitis in an outbreak in 1981 in Bombay, India: clinical and serologic studies. J Infect Dis. 1983;147(4):660–8.
24.
Wadia NH, Wadia PN, Katrak SM, Misra VP. A study of the neurological disorder associated with acute haemorrhagic conjunctivitis due to enterovirus 70. J Neurol Neurosurg Psychiatry. 1983;46(7):599–610.CrossRefPubMedPubMedCentral
25.
Katiyar BC, Misra S, Singh RB, Singh AK, Gupta S, Gulati AK, et al. Adult polio-like syndrome following enterovirus 70 conjunctivitis (natural history of the disease). Acta Neurol Scand. 1983;67(5):263–74.
26.
Yui LA, Gledhill RF. Limb paralysis as a manifestation of Coxsackie B virus infection. Dev Med Child Neurol. 1991;33(5):427–38.CrossRefPubMed
27.
28.
Grist NR, Roberts GB. Histological studies of Cox-sackie A7 poliomyelitis in man and monkeys. J Pathol Bacteriol. 1962;84:39–44.CrossRefPubMed
29.
Horner LM, Poulter MD, Brenton JN, Turner RB. Acute flaccid paralysis associated with novel enterovirus C105. Emerg Infect Dis. 2015;21(10):1858–60.CrossRefPubMedPubMedCentral
30.
Schuster JE, Selvarangan R, Hassan F, Briggs KB, Hays L, Miller JO, et al. Clinical course of enterovirus D68 in hospitalized children. Pediatr Infect Dis J. 2017;36(3):290–5.
31.
Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–105.CrossRefPubMed
32.
Wiechers D. Electrophysiology of acute polio revisited. Utilizing newer EMG techniques in vaccine-associated disease. Ann N Y Acad Sci. 1995;753:111–9.CrossRefPubMed
33.
Hovden IA, Pfeiffer HC. Electrodiagnostic findings in acute flaccid myelitis related to enterovirus D68. Muscle Nerve. 2015 Nov;52(5):909–10.CrossRefPubMed
34.
Choudhary A, Sharma S, Sankhyan N, Gulati S, Kalra V, Banerjee B, et al. Midbrain and spinal cord magnetic resonance imaging (MRI) changes in poliomyelitis. J Child Neurol. 2010;25(4):497–9.
35.
Kornreich L, Dagan O, Grunebaum M. MRI in acute poliomyelitis. Neuroradiology. 1996;38(4):371–2.CrossRefPubMed
36.
Malzberg MS, Rogg JM, Tate CA, Zayas V, Easton JD. Poliomyelitis: hyperintensity of the anterior horn cells on MR images of the spinal cord. AJR Am J Roentgenol. 1993;161(4):863–5.CrossRefPubMed
37.
•• Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence NV. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. Am J Neuroradiol. 2015;36(2):245–50. A review of the neuroimaging findings in EV-D68-associated AFP/AFM. CrossRefPubMedPubMedCentral
38.
Shen WC, Tsai C, Chiu H, Chow K. MRI of enterovirus 71 myelitis with monoplegia. Neuroradiology. 2000;42(2):124–7.CrossRefPubMed
39.
• Lugo D, Krogstad P. Enteroviruses in the early 21st century: new manifestations and challenges. Curr Opin Pediatr. 2016;28(1):107–13. A brief overview of recent developments regarding emerging enteroviruses, antiviral treatments, and vaccines. CrossRefPubMedPubMedCentral
40.
Nasri D, Bouslama L, Pillet S, Bourlet T, Aouni M, Pozzetto B. Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert Rev Mol Diagn. 2007 Jul;7(4):419–34.CrossRefPubMed
41.
42.
Grist NR, Bell EJ. Paralytic poliomyelitis and nonpolio enteroviruses: studies in Scotland. Rev Infect Dis. 1984;6(Suppl 2):S385–6.CrossRefPubMed
43.
Santhanam S, Choudhury DS. Coxsackie A-9 in the etiology of poliomyelitis-like diseases. Indian J Pediatr. 1985;52(417):405–8.CrossRefPubMed
44.
Chaves SS, Lobo S, Kennett M, Black J. Coxsackie virus A24 infection presenting as acute flaccid paralysis. Lancet. 2001;357(9256):605.CrossRefPubMed
45.
Laxmivandana R, Yergolkar P, Rajeshwari M, Chitambar SD. Genomic characterization of coxsackievirus type A24 strains associated with acute flaccid paralysis and rarely identified Hopkins syndrome. Arch Virol. 2014;159(11):3125–9.CrossRefPubMed
46.
Angez M, Shaukat S, Zahra R, Alam MM, Sharif S, Khurshid A, et al. Characterization of group B coxsackieviruses isolated from non-polio acute flaccid paralysis patients in Pakistan: vital assessment before polio eradication. Epidemiol Infect. 2017;145(12):2473–81.CrossRefPubMed
47.
Tao Z, Wang H, Liu Y, Li Y, Jiang P, Liu G, et al. Non-polio enteroviruses from acute flaccid paralysis surveillance in Shandong Province, China, 1988-2013. Sci Rep. 2014;4:6167.CrossRefPubMedPubMedCentral
48.
Dhole TN, Ayyagari A, Chowdhary R, Shakya AK, Shrivastav N, Datta T, et al. Non-polio enteroviruses in acute flaccid paralysis children of India: vital assessment before polio eradication. J Paediatr Child Health. 2009;45(7–8):409–13.
49.
Fernandez-Garcia MD, Kebe O, Fall AD, Ndiaye K. Identification and molecular characterization of non-polio enteroviruses from children with acute flaccid paralysis in West Africa, 2013-2014. Sci Rep. 2017;7(1):3808.CrossRefPubMedPubMedCentral
50.
•• Lopalco PL. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect. 2017;145(3):413–9. A detailed overview of wild and vaccine-derived polioviruses and progress towards polio erradication. CrossRefPubMed
51.
Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(Suppl 1):S380–9.CrossRefPubMed
52.
53.
Nathanson N, Langmuir AD. The cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. I. Background. Am J Hyg. 1963;78:16–28.PubMed
54.
Ohka S, Sakai M, Bohnert S, Igarashi H, Deinhardt K, Schiavo G, et al. Receptor-dependent and -independent axonal retrograde transport of poliovirus in motor neurons. J Virol. 2009;83(10):4995–5004.
55.
Bodian D. Histopathologic basis of clinical findings in poliomyelitis. Am J Med. 1949;6(5):563–78.CrossRefPubMed
56.
Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RW, Cochi SL. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine—a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med. 1995 Feb 23;332(8):500–6.CrossRefPubMed
57.
58.
Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol. 1967;85(2):297–310.CrossRefPubMed
59.
•• Dyda A, Stelzer-Braid S, Adam D, Chughtai AA, MacIntyre CR. The association between acute flaccid myelitis (AFM) and enterovirus D68 (EV-D68)—what is the evidence for causation? Euro Surveillance: bulletin Europeen sur les maladies transmissibles = European Communicable Disease Bulletin. 2018;23(3) A summary of the evidence for EV-D68 as a cause of AFP/AFM.
60.
Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA, Centers for Disease Control and Prevention. Enterovirus surveillance—United States, 1970-2005. Morbidity and mortality weekly report. Surveillance Summaries. 2006;55(8):1–20.PubMed
61.
Centers for Disease Control and Prevention. Clusters of acute respiratory illness associated with human enterovirus 68—Asia, Europe, and United States, 2008-2010. MMWR Morb Mortal Wkly Rep. 2011;60(38):1301–4.
62.
Abedi GR, Watson JT, Pham H, Nix WA, Oberste MS, Gerber SI. Enterovirus and human parechovirus surveillance—United States, 2009-2013. MMWR Morb Mortal Wkly Rep. 2015;64(34):940–3.CrossRefPubMed
63.
• Holm-Hansen CC, Midgley SE, Fischer TK. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis. 2016;16(5):e64–75. A review of EV-D68 emergence around the world that includes a summary of all studies to that point. CrossRefPubMed
64.
Edwin JJ, Reyes Domingo F, Booth TF, Showronski DM, Chambers C, Simmonds K, et al. Surveillance summary of hospitalized pediatric enterovirus D68 cases in Canada, September 2014. Can Commun Dis Rep (CCDR). 2015;41(S-1):2–8.CrossRef
65.
Oermann CM, Schuster JE, Conners GP, Newland JG, Selvarangan R, Jackson MA. Enterovirus d68. A focused review and clinical highlights from the 2014 U.S. outbreak. Ann Am Thorac Soc. 2015;12(5):775–81.CrossRefPubMed
66.
Imamura T, Oshitani H. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol. 2015;25(2):102–14.CrossRefPubMed
67.
Wei W, Guo H, Chang J, Yu Y, Liu G, Zhang N, et al. ICAM-5/telencephalin is a functional entry receptor for enterovirus D68. Cell Host Microbe. 2016;20(5):631–41.
68.
Meijer A, van der Sanden S, Snijders BE, Jaramillo-Gutierrez G, Bont L, van der Ent CK, et al. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in the Netherlands in 2010. Virology. 2012;423(1):49–57.CrossRefPubMed
69.
Tokarz R, Firth C, Madhi SA, Howie SR, Wu W, Sall AA, et al. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol. 2012;93(Pt 9):1952–8.CrossRefPubMedPubMedCentral
70.
• Zhang Y, Cao J, Zhang S, Lee AJ, Sun G, Larsen CN, et al. Genetic changes found in a distinct clade of enterovirus D68 associated with paralysis during the 2014 outbreak. Virus Evolution. 2016;2(1):vew015. A genomic analysis study that identified specific nucleotide substitutions that may have contributed to the neurovirulence of EV-D68.
71.
Kreuter JD, Barnes A, McCarthy JE, Schwartzman JD, Oberste MS, Rhodes CH, et al. A fatal central nervous system enterovirus 68 infection. Arch Pathol Lab Med. 2011;135(6):793–6.
72.
•• Hixon AM, Yu G, Leser JS, Yagi S, Clarke P, Chiu CY, et al. A mouse model of paralytic myelitis caused by enterovirus D68. PLoS Pathog. 2017;13(2):e1006199. A mouse model that demonstrates benefit of human IVIG that contains high anti-EV-D68 titers in reducing severity of paralysis.
73.
74.
Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304–9.CrossRefPubMed
75.
Melnick JL. Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. Rev Infect Dis. 1984;6(Suppl 2):S387–90.CrossRefPubMed
76.
Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000;31(3):678–83.CrossRefPubMed
77.
•• Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–18. A comprehensive 5-year population-based study of over seven million cases of hand, foot, and mouth disease and its complications in China.
78.
Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–90.CrossRefPubMed
79.
Podin Y, Gias EL, Ong F, Leong YW, Yee SF, Yusof MA, et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health. 2006;6:180.CrossRefPubMedPubMedCentral
80.
Hosoya M, Kawasaki Y, Sato M, Honzumi K, Kato A, Hiroshima T, et al. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J. 2006;25(8):691–4.
81.
Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, Sanjoh K, et al. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol. 2005;43(12):6171–5.
82.
Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics. 2007;120(2):e244–52.CrossRefPubMed
83.
Chung PW, Huang YC, Chang LY, Lin TY, Ning HC. Duration of enterovirus shedding in stool. J Microbiol Immunol Infect = Wei mian yu gan ran za zhi. 2001;34(3):167–70.PubMed
84.
•• Ong KC, Wong KT. Understanding enterovirus 71 neuropathogenesis and its impact on other neurotropic enteroviruses. Brain Pathol. 2015 Sep;25(5):614–24. A review of current knowledge regarding the pathogenesis of neurologic complications of EV-A71.
85.
• Huang PN, Shih SR. Update on enterovirus 71 infection. Current Opinion in Virology. 2014 Apr;5:98–104. A review of EV-A71 infection with focus on pathogenesis.
86.
Shih SR, Ho MS, Lin KH, Wu SL, Chen YT, Wu CN, et al. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. Virus Res. 2000;68(2):127–36.
87.
Singh S, Poh CL, Chow VT. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol Immunol. 2002;46(11):801–8.CrossRefPubMed
88.
Ooi MH, Wong SC, Podin Y, Akin W, del Sel S, Mohan A, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44(5):646–56.CrossRefPubMed
89.
Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15(7):798–801.
90.
Chang LY, Chang IS, Chen WJ, Huang YC, Chen GW, Shih SR, et al. HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics. 2008;122(6):1271–6.
91.
Han ZL, Li JA, Chen ZB. Genetic polymorphism of CCL2-2510 and susceptibility to enterovirus 71 encephalitis in a Chinese population. Arch Virol. 2014;159(9):2503–7.CrossRefPubMed
92.
Wong KT, Munisamy B, Ong KC, Kojima H, Noriyo N, Chua KB, et al. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J Neuropathol Exp Neurol. 2008;67(2):162–9.
93.
Wong KT, Chua KB, Lam SK. Immunohistochemical detection of infected neurons as a rapid diagnosis of enterovirus 71 encephalomyelitis. Ann Neurol. 1999;45(2):271–2.CrossRefPubMed
94.
Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, Lim WL, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998;133(6):795–8.CrossRefPubMed
95.
Yang Y, Wang H, Gong E, Du J, Zhao X, McNutt MA, et al. Neuropathology in 2 cases of fatal enterovirus type 71 infection from a recent epidemic in the People’s Republic of China: a histopathologic, immunohistochemical, and reverse transcription polymerase chain reaction study. Hum Pathol. 2009;40(9):1288–95.CrossRefPubMed
96.
Yan JJ, Wang JR, Liu CC, Yang HB, Su IJ. An outbreak of enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J Clin Virol. 2000;17(1):13–22.CrossRefPubMed
97.
Van Tu P, Thao NTT, Perera D, Truong KH, Tien NTK, Thuong TC, et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, Southern Vietnam, 2005. Emerg Infect Dis. 2007;13(11):1733–41.CrossRefPubMedPubMedCentral
98.
Ooi MH, Wong SC, Mohan A, Podin Y, Perera D, Clear D, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis. 2009;9:3.CrossRefPubMedPubMedCentral
99.
100.
Ooi MH, Solomon T, Podin Y, Mohan A, Akin W, Yusuf MA, et al. Evaluation of different clinical sample types in diagnosis of human enterovirus 71-associated hand-foot-and-mouth disease. J Clin Microbiol. 2007;45(6):1858–66.
101.
Tsai JD, Tsai HJ, Lin TH, Chang YY, Yang SH, Kuo HT. Comparison of the detection rates of RT-PCR and virus culture using a combination of specimens from multiple sites for enterovirus-associated encephalomyelitis during enterovirus 71 epidemic. Jpn J Infect Dis. 2014;67(5):333–8.CrossRefPubMed
102.
Perez-Velez CM, Anderson MS, Robinson CC, McFarland EJ, Nix WA, Pallansch MA, et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis. 2007;45(8):950–7.CrossRefPubMed
103.
Chang LY, Hsia SH, Wu CT, Huang YC, Lin KL, Fang TY, et al. Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J. 2004 Apr;23(4):327–32.CrossRefPubMed
104.
Cardosa J, Farrar J, Yeng C. A guide to clinical management and public health response to hand, foot and mouth disease (HFMD). 2011.
105.
Wang SM, Lei HY, Huang MC, Su LY, Lin HC, Yu CK, et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. Journal of Clinical Virology: the official publication of the Pan American Society for Clinical Virology 2006;37(1):47–52.
106.
Hayward JC, Gillespie SM, Kaplan KM, Packer R, Pallansch M, Plotkin S, et al. Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J. 1989;8(9):611–6.CrossRefPubMed
107.
Grard G, Drexler JF, Lekana-Douki S, Caron M, Lukashev A, Nkoghe D, et al. Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October-November 2010. Euro Surveillance: bulletin Europeen sur les maladies transmissibles = European Communicable Disease Bulletin. 2010;15(47)
108.
Lukashev AN, Drexler JF, Kotova VO, Amjaga EN, Reznik VI, Gmyl AP, et al. Novel serotypes 105 and 116 are members of distinct subgroups of human enterovirus C. The Journal of General Virology. 2012;93(Pt 11):2357–62.
109.
Goto K, Sanefuji M, Kusuhara K, Nishimura Y, Shimizu H, Kira R, et al. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis. 2009;15(10):1689–91.
110.
Solomon T, Kneen R, Dung NM, Khanh VC, Thuy TT, Ha DQ, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet. 1998;351(9109):1094–7.CrossRefPubMed
111.
Li J, Loeb JA, Shy ME, Shah AK, Tselis AC, Kupski WJ, et al. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol. 2003 Jun;53(6):703–10.
112.
Sejvar JJ, Bode AV, Marfin AA, Campbell GL, Ewing D, Mazowiecki M, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11(7):1021–7.
113.
Sejvar JJ, Bode AV, Marfin AA, Campbell GL, Pape J, Biggerstaff BJ, et al. West Nile virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006;12(3):514–6.
114.
Schellinger PD, Schmutzhard E, Fiebach JB, Pfausler B, Maier H, Schwab S. Poliomyelitic-like illness in central European encephalitis. Neurology. 2000;55(2):299–302.CrossRefPubMed
115.
Bender A, Schulte-Altedorneburg G, Walther EU, Pfister HW. Severe tick borne encephalitis with simultaneous brain stem, bithalamic, and spinal cord involvement documented by MRI. J Neurol Neurosurg Psychiatry. 2005;76(1):135–7.CrossRefPubMedPubMedCentral
116.
Lindsey NP, Hayes EB, Staples JE, Fischer M. West Nile virus disease in children, United States, 1999-2007. Pediatrics. 2009;123(6):e1084–9.CrossRefPubMed
117.
• Abzug MJ. The enteroviruses: problems in need of treatments. J Infect. 2014 Jan;68(Suppl 1):S108–14. A review of emerging antiviral compounds for the treatment of enterovirus infections (including EV-D68 and EV-A71).
118.
Rhoden E, Zhang M, Nix WA, Oberste MS. In vitro efficacy of antiviral compounds against enterovirus D68. Antimicrob Agents Chemother. 2015 Dec;59(12):7779–81.CrossRefPubMedPubMedCentral
119.
• Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antivir Res. 2016;131:61–5. A study of in vitro efficacy of emerging antiviral compounds for EV-D68 and EV-A71. CrossRefPubMed
120.
Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sanchez PJ, et al. A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J Pediatr Infect Dis Soc. 2016;5(1):53–62.CrossRef
121.
• Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, et al. Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. J Infect Dis. 2017;215(3):335–43. A study that lays the groundwork for the possible use of pocapavir in global polio erradication efforts. PubMed
122.
Torres-Torres S, Myers AL, Klatte JM, Rhoden EE, Oberste MS, Collett MS, et al. First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis. Pediatr Infect Dis J. 2015 Jan;34(1):52–4.
123.
Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother. 2005;49(2):619–26.CrossRefPubMedPubMedCentral
124.
Zhang X, Song Z, Qin B, Zhang X, Chen L, Hu Y, et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antivir Res. 2013;97(3):264–9.
125.
Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47(12):3907–16.
126.
Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;49(6):2267–75.
127.
Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother. 2012;56(9):4838–44.CrossRefPubMedPubMedCentral
128.
Ulferts R, van der Linden L, Thibaut HJ, Lanke KH, Leyssen P, Coutard B, et al. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother. 2013;57(4):1952–6.CrossRefPubMedPubMedCentral
129.
Tyler KL. Rationale for the evaluation of fluoxetine in the treatment of enterovirus D68-associated acute flaccid myelitis. JAMA Neurol. 2015;72(5):493–4.CrossRefPubMedPubMedCentral
130.
Gofshteyn J, Cardenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol. 2016;64:94–8.CrossRefPubMed
131.
Li ZH, Li CM, Ling P, Shen FH, Chen SH, Liu CC, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197(6):854–7.
132.
Kang H, Kim C, Kim DE, Song JH, Choi M, Choi K, et al. Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antivir Res. 2015 Dec;124:1–10.
133.
•• Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28. A study demonstrating vaccine efficacy in the prevention of EV-A71-associated hand, foot, and mouth disease as well as neurologic complications. CrossRefPubMed
134.
•• Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37. A study demonstrating vaccine efficacy in the prevention of EV-A71-associated hand, foot, and mouth disease. CrossRefPubMed
135.
•• Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024–32. A study demonstrating vaccine efficacy in the prevention of EV-A71-associated hand, foot, and mouth disease as well as neurologic complications.
136.
• Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, et al. 2-year efficacy, immunogenicity, and safety of Vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215(1):56–63. A follow-up study demonstrating sustained immunogenicity and protection from EV-A71 disease for the second year post vaccination. CrossRefPubMed
137.
138.
Wang W, Song J, Wang J, Li Y, Deng H, Li M, et al. Cost-effectiveness of a national enterovirus 71 vaccination program in China. PLoS Negl Trop Dis. 2017;11(9):e0005899.
139.
Zhang C, Zhang X, Zhang W, Dai W, Xie J, Ye L, et al. Enterovirus D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice. Emerg Microbes Infect. 2018;7(1):3.
140.
Dai W, Zhang C, Zhang X, Xiong P, Liu Q, Gong S, et al. A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice. Vaccine. 2018;36(5):653–9.
Metadaten
Titel
Acute Flaccid Paralysis and Enteroviral Infections
verfasst von
Ari Bitnun
E. Ann Yeh
Publikationsdatum
01.09.2018
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 9/2018
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-018-0641-x

Weitere Artikel der Ausgabe 9/2018

Current Infectious Disease Reports 9/2018 Zur Ausgabe

Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

Hospital-Acquired Infections Under Pay-for-Performance Systems: an Administrative Perspective on Management and Change

Tropical, Travel and Emerging Infection (L Chen and A Boggild, Section Editors)

Evolving Epidemiology of Japanese Encephalitis: Implications for Vaccination

Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

The Current State of Antimicrobial Stewardship: Challenges, Successes, and Future Directions

Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools

Tropical, Travel, and Emerging Infections (L Chen and A Boggild, Section Editors)

Travel and the Spread of Drug-Resistant Bacteria

Female Genital Tract Infections (J Sobel, Section Editor)

Ureaplasma urealyticum: the Role as a Pathogen in Women’s Health, a Systematic Review

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise